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Background: Cervical cancer is the fourth most frequent malignancy affecting women 
worldwide, but drug resistance and toxicities remain a major challenge in chemotherapy. The 
use of natural compounds is promising because they are less toxic and able to target multiple 
signaling pathways. The 1′S-1′-acetoxychavicol acetate (ACA), a natural compound isolated 
from wild ginger Alpinia conchigera, induced cytotoxicity on various cancer cells including 
cervical cancer. MicroRNAs (miRNAs) are short noncoding RNAs that regulate numerous 
biological processes, such as apoptosis and chemosensitivity. Past studies reported that miR-629 
is upregulated in many cancers, and its expression was altered in ACA-treated cervical cancer 
cells. However, the role of miR-629 in regulating sensitivity toward ACA or other anticancer 
agents has not been reported. Hence, this study aims to investigate the role of miR-629 in 
regulating response toward ACA on cervical cancer cells.
Methods: The miR-629 expression following transfection with miR-629 hairpin inhibitor and 
hairpin inhibitor negative control was measured using quantitative real-time polymerase chain 
reaction (RT-qPCR). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay was used to investigate sensitivity toward ACA. Apoptosis was detected using Annexin 
V/propidium iodide and Caspase 3/7 assays. The gene target for miR-629 was identified using 
miRNA target prediction programs, luciferase reporter assay and Western blots. Gene overex-
pression studies were performed to evaluate its role in regulating response toward ACA.
Results: Transfection with miR-629 hairpin inhibitor downregulated its expression in both 
cervical cancer cell lines. Suppression of miR-629 increased sensitivity toward ACA by reducing 
cell proliferation and inducing apoptosis. Luciferase reporter assay confirmed RSU1 as a direct 
target of miR-629. Overexpression of miR-629 decreased RSU1 protein expression, while 
inhibition of miR-629 increased RSU1 protein expression. Overexpression of RSU1 augmented 
antiproliferative and apoptosis-inducing effects of ACA.
Conclusion: Our findings showed that combination of ACA with miR-629 and RSU1 may 
provide a potential strategy in treating cervical cancer.
Keywords: miR-629, 1′-acetoxychavicol acetate, cervical cancer, Ras suppressor-1, apoptosis, 
cell proliferation
Introduction
Cancer of the cervix is the fourth most common malignancy affecting women worldwide 
after breast cancer. In 2012, there were an estimated 527,600 new cases diagnosed and 
265,700 mortalities worldwide, with the highest incidences happening in less developed 
countries.1 Chemotherapy is often used together with surgery and radiotherapy to 
treat cervical cancer in combinatorial approach. However, poor clinical outcomes 
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and treatment failures still occur, especially in recurrent or 
advanced cervical cancer, due to the development of drug 
resistance and toxicities.2,3 Thus, it is necessary to identify 
new therapeutic strategies to improve overall response and 
survival outcome in cervical cancer patients.
Natural compounds have been used in cancer treatment 
for many years either as stand-alone or as adjuvant to improve 
therapeutic efficacy. They are able to target multiple signaling 
pathways and are less toxic compared to some conventional 
anticancer agents.4 Oncovin (vincristine), Velban (vinblastine), 
Hycamtin (topotecan) and Taxol (paclitaxel) are some examples 
of natural compounds derived from plants currently used in che-
motherapy to treat various cancers.5 The 1′S-1′-acetoxychavicol 
acetate (ACA) is a natural compound isolated from the wild 
ginger, Alpinia conchigera. We have previously reported that 
it is able to induce cytotoxicity when used as stand-alone and 
potentiates the effects of cisplatin when used in combination 
on different cancer cells including cervical cancer.6,7
MicroRNAs (miRNAs) are short noncoding RNAs that 
regulate genes posttranscriptionally by suppressing translation 
or inducing messenger RNA (mRNA) degradation.8 Studies 
have shown that miRNAs are dysregulated in many cancers and 
they play crucial roles in regulating a wide variety of biologi-
cal processes such as cell death, metastasis, cell proliferation 
and chemosensitivity.9–13 In a study carried out by a group of 
researchers to analyze miRNA expression profiles across mul-
tiple cancers using data sets obtained from The Cancer Genome 
Atlas (TCGA), miR-629 was found to be upregulated in various 
cancers, such as bladder, head and neck, lung, kidney, breast 
and uterine cancer.14 It was also reported that circulating miR-
629 is upregulated in lung cancer patients and can potentially 
be used in diagnosis of lung and gastric cancer.15,16
In this study, we first showed that suppression of miR-629 
in cervical cancer cells enhanced sensitivity toward ACA by 
reducing cell proliferation and inducing apoptosis. We next 
identified and confirmed RSU1 as a direct target of miR-629 
and found that overexpression of miR-629 reduced RSU1 
protein expression, whereas inhibition of miR-629 increased 
RSU1 protein expression. Furthermore, we demonstrated 
that overexpression of RSU1 augmented antiproliferative 
and apoptosis-inducing effects of ACA.
Materials and methods
cell culture and aca
Human cervical cancer cells Ca Ski and SiHa were procured 
from American Type Cell Culture (ATCC, Manassas, VA, 
USA) and cultured in Roswell Park Memorial Institute 
(RPMI)-1640 (HyClone, Logan, UT, USA) and DMEM 
(HyClone) supplemented with 10% (v/v) fetal bovine 
serum (HyClone), respectively. All cells were maintained in 
humidified incubator containing 5% CO
2
 at 37°C. The ACA 
was provided by the Centre for Natural Product Research 
and Drug Discovery (CENAR), Department of Chemistry, 
University of Malaya, Malaysia.
Transfection
For miRNA transfection, cells were transfected with 
100 nM of miRIDIAN microRNA human hsa-miR-629 
mimic or miRIDIAN microRNA human hsa-miR-629 
hairpin inhibitor (Thermo Fisher Scientific, Waltham, MA, 
USA), using DharmaFECT 1 Transfection Reagent (Thermo 
Fisher Scientific) for 24 h according to the manufacturer’s 
protocol. miRIDIAN microRNA Mimic Negative Control #1 
and miRIDIAN microRNA Hairpin Inhibitor Negative Control 
#1 (Thermo Fisher Scientific) were used as negative controls.
For plasmid transfection, cells were transfected with 
50 ng of pCMV6-RSU1 (Origene Technologies, Rockville, 
MD, USA) using DharmaFECT 1 Transfection Reagent 
(Thermo Fisher Scientific) for 12 h according to manufacturer’s 
protocol. The empty vector pCMV6 (Origene Technologies) 
was used as negative control.
Quantitative real-time polymerase 
chain reaction (rT-qPcr)
The total RNA was extracted using miRNeasy Mini Kit 
(Qiagen, Venlo, the Netherlands) and reverse-transcribed into 
cDNA with TaqMan® MicroRNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s protocol using Veriti 96-well Thermal Cycler 
(Applied Biosystems). The TaqMan MicroRNA Assays 
(Applied Biosystems) were used to quantified miR-629 
expression according to the manufacturer’s protocol using 
a Bio-Rad CFX96™ Real-Time PCR Detection System 
(Bio-Rad Laboratories, Hercules, CA, USA) and analyzed 
by Bio-Rad CFX Manager v2.1 (Bio-Rad Laboratories). The 
U6 small nuclear RNA was used to normalize RNA input. 
Fold changes were calculated using the 2−ΔΔCt method and 
presented as normalized fold expression.
cell proliferation assay
Transfected cells were treated with ACA for 12 h 
(plasmid transfection) or 48 h (miRNA transfection). 
A total of 30 µL of 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) reagent (Merck, 
Kenilworth, NJ, USA) (5.0 mg/mL) was added into each well 
and incubated in the dark at 37°C for 1 h. Media containing 
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excess MTT reagent were then aspirated and 200 µL dim-
ethyl sulfoxide (Merck) was added to dissolve the purple 
formazan precipitates. Results were obtained using microtiter 
plate reader (Tecan, Männedorf, Zürich, Switzerland), which 
detects absorbance wavelength at 570 nm.
annexin V/propidium iodide (Pi) assay
Transfected cells were treated with ACA (20 µM for Ca Ski 
and 30 µM for SiHa) for 12 h (plasmid transfection) or 48 h 
(miRNA transfection). Apoptosis assays were carried out using 
BD Pharmingen™ Annexin V-FITC Apoptosis Detection Kit 
(BD Biosciences, Franklin Lakes, NJ, USA) according to the 
manufacturer’s protocol. Results were obtained using BD 
FACSCanto II flow cytometer (BD Biosciences) and analyzed 
with BD FACSDiva software (BD Biosciences).
caspase 3/7 assay
Transfected cells were treated with ACA (20 µM for 
Ca Ski and 30 µM for SiHa) for 6 h (plasmid transfection) 
or 12 h (miRNA transfection). The activities of caspases 3 
and 7 were then measured with Caspase-Glo® 3/7 Assay 
(Promega, Fitchburg, WI, USA) according to the manufac-
turer’s protocol using GloMax®-Multi Jr (Promega).
Bioinformatic analyses of mir-629′s 
putative targets
miRNA target prediction programs TargetScan v7.1 and 
miRanda were used to identify potential targets of miR-629. 
The predicted targets were then subjected to gene annota-
tion enrichment analysis using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.8.
Vector construction
The total RNA was first converted into cDNA using 
RevertAid First Strand cDNA (Thermo Fisher Scientific). 
The 3′-UTR regions of RSU1 containing the predicted 
binding site were then amplified from the cDNA and 
inserted into the pmirGLO Dual-Luciferase miRNA Target 
Expression Vector (Promega) to construct the luciferase 
reporter plasmids. Mutations in the predicted binding site 
for RSU1 were performed using the QuikChange Multi Site-
Directed Mutagenesis Kit (Stratagene, San Diego, CA, USA) 
according to the manufacturer’s protocol. The sequences of 
the constructs were then verified by sequencing.
luciferase assay
Cells were cotransfected with 40 ng of 3′-UTR reporter 
constructs containing wild-type or mutated binding sites 
and 100 nM of miR-629 mimic or negative control using 
DharmaFECT 1 Transfection Reagent (Thermo Fisher 
Scientific). Firefly and Renilla luciferase activities were 
assayed 48 h after transfection with Dual-Glo® Luciferase 
Assay System (Promega) according to the manufacturer’s 
protocol using GloMax-Multi Jr (Promega). The firefly 
luciferase activity was normalized to Renilla activity, which 
was used as an internal control.
Western blot
Proteins were extracted using radioimmunoprecipitation assay 
buffer containing 1× Halt Protease and Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific) and quantified using BCA 
Protein Assay Kit (Pierce, Waltham, MA, USA) according to 
manufacturer’s protocol. Total cell lysates were fractionated 
by 12% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and electroblot onto nitrocellulose 
membranes. Nonspecific binding sites of membranes were 
blocked for 1 h with 5% (w/v) nonfat milk in 1× TBST (1× Tris 
buffered saline [TBS] with 0.1% [v/v] Tween-20). Membranes 
were then incubated at 4°C overnight with primary antibodies 
against RSU1 (1:1,000; Abcam, Cambridge, UK) and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1,000; 
Cell Signaling Technology, Danvers, MA, USA), washed 
with 1× TBST and followed by incubation with secondary 
immunoglobulin G (IgG) horseradish peroxidase (HRP)-
linked antibody and antibiotin HRP-linked antibody (1:1,000; 
Cell Signaling Technology). Membranes were then washed 
with 1× TBST and 1× TBS, and bands were visualized using 
WesternBright Quantum (Advansta, Menlo Park, CA, USA) 
on the Fusion FX7 system (Vilber Lourmat, Torcy, Marne 
La Vallée, France) and quantified using the ImageJ Analyst 
software (NIH, Bethesda, MD, USA), with band intensities 
normalized to GAPDH, which was used as loading control.
statistical analysis
All experiments were carried out in triplicates and presented as 
mean values ± standard error mean. Mann–Whitney U-test was 
used to evaluate the statistical significance of results, whereby 
P-value ,0.05 was considered as statistically significant.
Results
aca downregulates mir-629 expression 
and suppression of mir-629 enhances 
sensitivity toward aca
To study the response of miR-629 toward ACA, the expression 
of miR-629 was determined using RT-qPCR following 
treatment with ACA. Figure 1A shows that miR-629 is 
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downregulated following treatment with ACA in both Ca Ski 
and SiHa cells. To explore the role of miR-629, we transfected 
Ca Ski and SiHa cells with miR-629 hairpin inhibitor and 
hairpin inhibitor negative control. Figure 1B shows successful 
inhibition of miR-629 expression level in both cell lines after 
transfection. To investigate the effects of ACA when miR-629 
is downregulated, MTT cell viability assays were carried out. 
Results showed that transfection with miR-629 hairpin inhibi-
tor enhanced sensitivity toward ACA, as shown by the decrease 
in the half maximal inhibitory concentration (IC
50
) values 
for ACA in Ca Ski (Figure 1C) and SiHa (Figure 1D) cells. 
However, overexpression of miR-629 did not cause significant 
differences in sensitivity toward ACA (Figure S1).
suppression of mir-629 increases sensitivity 
toward aca by inducing apoptosis
To assess if combination of miR-629 hairpin inhibitor 
and ACA modulates apoptosis, both Annexin V/PI and 
Caspase 3/7 assays were employed. Results showed that 
suppression of miR-629 promoted induction of apoptosis 
when cells were treated with ACA, as shown by the increased 
apoptosis level in Figure 2A and higher Caspase 3/7 activity 
in Figure 2B. These results indicated that suppression of 
miR-629 increases sensitivity toward ACA by inducing 
apoptosis. On the other hand, no obvious differences in 
apoptosis were detected when miR-629 overexpressing cells 
were treated with ACA (Figure S2).
Mir-629 directly targets the 3′UTr 
of rsU1
The hypothetical signaling network depicting the interac-
tion between miR-629 and its putative targets revealed that 
miR-629′s putative targets are involved in regulating cell 
proliferation and apoptosis (Figure 3). RSU1, which was cho-
sen based on scores, novelty and function, was identified as a 
potential target by TargetScan v7.1 and miRanda (Figure 4A). 
Figure 1 aca downregulates mir-629 expression and suppression of mir-629 enhances sensitivity toward aca. (A) expression level of mir-629 as measured by rT-qPcr 
following treatment with aca. (B) expression level of mir-629 as measured by rT-qPcr after transfection with mir-629 hairpin inhibitor. (C, D) Dose–response curves on 
ca ski (C) and siha (D) cells transfected with mir-629 hairpin inhibitor followed by treatment with aca.
Note: **P,0.05.
Abbreviations: aca, 1′s-1′-acetoxychavicol acetate; rT-qPcr, quantitative real-time polymerase chain reaction.
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Figure 2 suppression of mir-629 increases aca-induced apoptosis. (A) apoptosis effects on cells transfected with mir-629 hairpin inhibitor followed by exposure to aca. 
(B) caspase 3/7 activity on cells transfected with mir-629 hairpin inhibitor followed by exposure to aca.
Notes: **P,0.05 in comparison to hairpin inhibitor negative control treated with aca; ##P,0.05 in comparison to untreated samples.
Abbreviation: aca, 1′s-1′-acetoxychavicol acetate.
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Figure 3 hypothetical signaling network depicting the interaction between mir-629 and its putative targets.
Notes: Orange colored symbols denote mir-629′s targets, whereas clear colored symbols denote targets unaffected by miR-629. Inhibitory relationships denote as flat 
arrow heads, whereas positive interactions denote as open arrow heads.
Abbreviations: aca, 1′s-1′-acetoxychavicol acetate; akt, protein kinase B; asK1, apoptosis signal-regulating kinase 1; Bcl-2, B-cell lymphoma 2; Bad, Bcl-2-associated 
death promoter; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2-like protein 4; casp 3, caspase-3; casp 8, caspase-8; cDK 4/6, cyclin-dependent kinase 4/6; DaXX, 
death-associated protein 6; Dvl, dishevelled; egr, epidermal growth factor; egFr, epidermal growth factor receptor; erK, extracellular signal-regulated kinase; FaDD, 
Fas-associated death domains; FAK, focal adhesion kinase; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; FOXO1, forkhead box O1; FZD, frizzled; 
grB2, growth factor receptor-bound protein 2; gsK3β, glycogen synthase kinase 3 beta; iTg, integrin; JnK, c-Jun n-terminal kinase; MDM2, mouse double minute 2 
homolog; MeK, mitogen-activated protein kinase kinase; p15, cyclin-dependent kinase 4 inhibitor B; p21, cyclin-dependent kinase inhibitor 1a; p53, protein p53; Pi3K, 
phosphoinositide 3-kinase; PUMA, p53-upregulated-modulator of apoptosis; SOS, son of sevenless; Raf, rapidly accelerated fibrosarcoma; RSU1, Ras suppressor-1; TCF/LEF, 
T-cell factor/lymphoid enhancer factor; TgFβ, transforming growth factor beta; TgFβr, transforming growth factor beta receptor; TriM33, tripartite motif containing 33; 
WnT, wingless-type MMTV integration site family.
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Binding site predicted by TargetScan v7.1
Binding site predicted by miRanda
RSU1 3′-UTR ...CUGUCUCUCAAA–UAAACCCA...3′5′
. ..UCAAGAGGGUUGCAUUUGGGU...5′miR-629 3′
RSU1 3′-UTR ...CUGUCUCUCAA –AUAAACCCA...3′5′
Mutated RSU1 3′-UTR ...CUGAGAGAGUUUAUUUGGGU...3′5′
miR-629 ...UCAAGAGGGUUGCAUUUGGGU...5′3′
Figure 4 mir-629 directly targets rsU1. (A) rsU1 protein expression following treatment with aca. (B) Predicted binding site between mir-629 and rsU1 3′-UTr 
and sequence of mutated rsU1 3′-UTr. (C) luciferase activity for cells cotransfected with wild-type rsU1 3′-UTr or mutated rsU1 3′-UTr and mir-629 mimic or 
mimic negative control. (D) rsU1 protein expression following transfection with mir-629 mimic, mimic negative control, mir-629 hairpin inhibitor or hairpin inhibitor 
negative control.
Note: **P,0.05.
Abbreviations: aca, 1′s-1′-acetoxychavicol acetate; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; UTr, untranslated region.
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Figure 5 Transfection with pcMV6-rsU1 upregulates rsU1 protein expression level and reduces cell viability on aca-treated cells. (A) rsU1 protein expression level 
following transfection with pcMV6-rsU1. (B) cell viability assay on rsU1-overexpressing cells treated with aca.
Note: **P,0.05.
Abbreviations: aca, 1′s-1′-acetoxychavicol acetate; gaPDh, glyceraldehyde 3-phosphate dehydrogenase.
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To study the response of RSU1 toward ACA, the expression 
of RSU1 was determined using Western blot following treat-
ment with ACA. Figure 4B shows that RSU1 is upregulated 
following treatment with ACA in both Ca Ski and SiHa cells. 
To confirm the direct interaction, luciferase reporter assay 
was performed. As shown in Figure 4C, luciferase activity 
was significantly decreased when cells were cotransfected 
with miR-629 mimic and luciferase reporter vector contain-
ing the wild-type sequence. However, no obvious differences 
were observed when the binding site is mutated. This 
confirmed that RSU1 is a direct target of miR-629. To assess 
if miR-629 can regulate the expression of RSU1, Western 
blots were carried out. Figure 4D shows that miR-629 mimic 
significantly reduced the expression of RSU1. Conversely, 
the expression of RSU1 was significantly increased when 
miR-629 is suppressed. Collectively, these results revealed 
that miR-629 directly targets RSU1.
Overexpression of rsU1 increases rsU1 
protein expression level and reduces 
cell viability
To elucidate the role of RSU1 in regulating response toward 
ACA, RSU1 was overexpressed using pCMV6-XL5 vector 
containing RSU1 sequence (pCMV6-RSU1) while empty 
vector lacking RSU1 sequence (pCMV6) served as negative 
control. As seen in Figure 5A, an increase in the RSU1 
protein expression level was observed in both cell lines after 
transfection with pCMV6-RSU1. To investigate the effects of 
RSU1 overexpression and ACA on cell viability, MTT cell 
viability assay was performed. Results showed a significant 
reduction in cell viability when RSU1 is overexpressed 
and treated with ACA (Figure 5B), indicating that RSU1 
enhanced sensitivity toward ACA.
rsU1 overexpression increases  
aca-induced apoptosis
To evaluate if the inhibitory effects of RSU1 overexpression 
in combination with ACA were mediated by apoptosis, 
both Annexin V/PI and Caspase 3/7 assays were used. 
As shown in Figure 6A, overexpression of RSU1 increased 
apoptosis level when treated with ACA. Likewise, a marked 
increase in Caspase 3/7 activity was observed on RSU1-
overexpressing cells treated with ACA (Figure 6B). These 
results indicated that overexpression of RSU1 increases 
ACA-induced apoptosis.
Discussion
Many studies have demonstrated that miRNAs play an 
important role in cancer initiation and progression.17 
Interestingly, a single miRNA is able to target different genes, 
enabling them to simultaneously regulate multiple signaling 
pathways.18 Different studies have reported that antican-
cer agents such as plant-derived natural compounds can 
modulate miRNA expression, and alterations in these miRNA 
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expression can affect their anticancer activities.19 Studies have 
shown that cancer is a multistage process caused by gene 
alterations in more than one signaling pathway.20 Therefore, 
the use of combination therapy involving natural compounds 
and miRNAs targeting could possibly help to improve thera-
peutic efficacy due to their pleiotropic effects.
Although miR-629 is overexpressed in many cancers, 
there is only a few published work on the role of miR-629 
in cancer.14 Past studies have demonstrated that miR-629 
plays an important role in hepatocellular carcinogenesis by 
regulating HNF4α-miRNA inflammatory feedback circuit 
and increases lung cancer risk by targeting tumor suppressor 
NBS1 gene.21,22 It was also revealed that miR-629 is upregu-
lated in clear cell renal cell carcinoma and accelerates cell 
motility and invasion by targeting tripartite motif-containing 
33 (TRIMM33), a tumor suppressor.23 We have also 
previously reported that miR-629 expression is dysregulated 
following treatment with ACA in cervical cancer cells.7 
However, the mechanistic role of miR-629 in regulating 
response toward anticancer agents has not been reported. 
Both HPV-16 positive Ca Ski and SiHa cells were used in 
this study because it was previously reported that HPV-
positive cervical cancer cell lines exhibited high expression 
of miR-629, partly due to the continuous expression of E6/E7 
in these cells.24 Our results showed that downregulation of 
miR-629 enhanced sensitivity toward ACA by reducing cell 
proliferation and increasing apoptosis, indicating that miR-
629 could also play a role in regulating response toward 
anticancer agents.
In addition, we also demonstrated that miR-629 directly 
binds to RSU1, a tumor suppressor capable of suppress-
ing Ras-dependent oncogenic transformation, and inhibits 
anchorage independent growth.25–27 A study by Donthamsetty 
et al showed that ectopic expression of RSU1 suppressed 
cell proliferation and migration in hepatocellular cancer 
cells. It was suggested in the same study that RSU1 could 
play a role in regulating liver size and tumorigenesis in mice 
together with particularly interesting new cysteine-histidine-
rich protein (PINCH).28 More recently, it was reported that 
RSU1 is able to hinder proliferation by inhibiting prosurvival 
PINCH-1 and promote apoptosis by activating proapoptotic 
p53-upregulated modulator of apoptosis (PUMA) in breast 
cancer cells.29 Nevertheless, its role in regulating response 
toward anticancer agents has also not been reported. 
In this study, we demonstrated that overexpression of RSU1 
augments antiproliferative and apoptosis-inducing effects of 
ACA, indicating that this tumor suppressor could also play a 
role in regulating sensitivity toward anticancer agents. Apart 
from RSU1, however, we could not rule out the possibility 
that other targets of miR-629 could also mediate sensitivity 
toward ACA, as there are many other targets which remain 
unvalidated.
Conclusion
We demonstrated that suppression of miR-629 enhanced 
sensitivity toward ACA by reducing cell proliferation and 
inducing apoptosis. We also identified RSU1 as a direct target 
of miR-629 and showed that RSU1 expression is regulated 
by miR-629. Furthermore, we revealed that overexpression 
of RSU1 augmented antiproliferative and apoptosis-inducing 
effects of ACA. To the best of our knowledge, this is the first 
study which demonstrated that miR-629 and RSU1 play a 
role in regulating response toward anticancer agents. Taken 
together, our findings showed that combination of ACA 
8QWUHDWHG $&$ S&09568$&$ S&09$&$















&
DVS
DVH

DFW
LYLW\
$SR
SWR
WLFF
HOOV
  

  
%$
&DVNL 6L+D&DVNL 6L+D
Figure 6 Overexpression of rsU1 augments aca-induced apoptosis. (A) apoptosis effects on rsU1-overexpressing cells treated with aca. (B) caspase 3/7 activity on 
rsU1-overexpressing cells treated with aca.
Notes: **P,0.05 in comparison to hairpin inhibitor negative control treated with aca; ##P,0.05 in comparison to untreated samples.
Abbreviation: aca, 1′s-1′-acetoxychavicol acetate.
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with miR-629 and RSU1 may provide a potential strategy 
in treating cervical cancer.
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Supplementary materials
Figure S1 mir-629 mimic upregulates mir-629 expression but did not enhance sensitivity toward aca. (A) rT-qPcr after transfection with mir-629 mimic. (B) ic50 values 
for aca on cells transfected with mir-629 mimic followed by treatment with aca.
Note: **P,0.05.
Abbreviations: aca, 1′s-1′-acetoxychavicol acetate; ic50, half maximal inhibitory concentration; rT-qPcr, quantitative real-time polymerase chain reaction.
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Figure S2 Upregulation of mir-629 does not affect aca-induced apoptosis. (A) relative apoptosis on cells transfected with mir-629 mimic followed by exposure to aca. 
(B) caspase 3/7 activity on cells transfected with mir-629 mimic followed by exposure to aca.
Abbreviation: aca, 1′s-1′-acetoxychavicol acetate.
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